To estimate the direct costs associated to outpatient and hospital care of diseases related to alcohol consumption in the Brazilian Unified Health System.
INTRODUCTION
Although alcohol consumption and related problems can vary around the world, the burden of alcohol-related diseases affects most countries. The World Health Organization (WHO, 2010) a states that the use of alcohol is one of the main risk factors for poor health, premature deaths, disabilities, and global burden of disease, compromising both individual and social development. The WHO also estimates that, in 2004, 2.5 million individuals worldwide died of alcohol-related causes, which represents around 4.0% of the total number of deaths a . Thirteen percent of them were people aged between 15 and 29 years. Approximately 4.5% of the global burden of disease and injury is attributable to alcohol, although these figures can vary from 1.3% to 12.1% across the world 7 .
The cost of alcohol consumption to the health sector is not restricted to the treatment of alcohol dependence alone, but also to a set of alcohol-related diseases. 4 Alcohol causes more than 30 diseases listed in the 10 th International Classification of Diseases (ICD-10), and works as a component cause for over 200 diseases b . The impact of alcohol use on these conditions depends on two aspects: the volume consumed and the pattern of drinking.
A systematic review 9 reported that, despite the discrepancies in the estimation methods and cost components used across different studies, findings on the substantial economic burden of alcohol on society are consistent. The authors estimated that the economic burden of alcohol accounts for 0.5% to 5.4% of the gross domestic product. The socioeconomic development level of countries, regions, and individuals is inversely associated with the burden of alcohol-related diseases c . In order to estimate the global burden of harm related to alcohol, WHO classifies countries using a four-point risk scale (1 [low] to 4 [high]) according to the pattern of its alcohol consumption. Data have shown that this scale can be equated to morbid-mortality rates attributable to alcohol consumption. Brazil is classified as level 4 6 . This study aimed to estimate the specific direct costs (medical costs) associated with outpatient and inpatient care of alcohol-related diseases in the Brazilian Unified Health System (SUS).
METHODS
To assess health care costs for alcohol-related diseases, it is necessary to apply the population attributable risk (PAR) for alcohol to the number of patients with a related disease. The population attributable risk is the proportion of the incidence of a disease in the population exposed to a particular risk factor that would, consequently, be eliminated if exposure was eliminated.
For PAR calculation, we selected diseases based on two criteria: (i) relative risk (RR) for alcohol consumption ≥ 1.20, which included oropharyngeal cancer, esophageal cancer, laryngeal cancer, liver cancer, breast cancer, hypertension, liver cirrhosis, and chronic pancreatitis; and (ii) RR for alcohol consumption ≥ 1.10 and < 1.20, if the disease was considered a relevant public health problem because of its prevalence. No disease met this criterion.
The exposure category was 25 g/day or more of ethanol and the reference group was comprised of individuals referred to in the studies as abstemious.
We estimated PAR using Levin's formula where Pe is the prevalence of exposure and RR the relative risk.
We searched for meta-analyses presenting RR estimates associated with the presence of alcohol consumption. As well as identifying the most recent meta-analyses, we also looked for large individual studies published after the search period covered by the meta-analyses. Literature was searched in Medline and Scopus databases. All the searches contained two blocks of concepts: one of the descriptors of exposure ("alcohol-related disorder*", "alcohol drinking", "alcohol intake", "alcohol-related disease*") and one of descriptors related to the selected diseases.
The meta-analyses quality was evaluated using the Assessing the Methodological Quality of Systematic Reviews (AMSTAR) inventory 8 . The meta-analyses carried out by Barnardi et al. . The study defined one drink for women (15 g/day of ethanol) and two drinks for men (30 g/day of ethanol) as hazardous consumption. Thus, we used the RR provided in the meta-analyses of 25 g/day ethanol, as this was closest to the category that the INCA survey referred to as hazardous consumption. The assumption behind this decision was that the distribution of alcohol use over 25 g/day of ethanol is expected to be skewed to the right, which means that most individuals that consume more than 25 g/day are closer to this value than to the other extreme of the distribution.
The study report did not provide data stratified by sex, as its main objective was to estimate the prevalence of tobacco use. The figures by sex used in our analysis were kindly provided by INCA. Data were unavailable for nine of the 26 state capitals of Brazil. The median of the proportion of hazardous consumption from other capitals in the same region was used to replace the missing information. . These open access databases provide aggregate information on the amount of money reimbursed by the government to the organizations that provide the health care (inpatient and outpatient) needed to treat and monitor these diseases.
We stratified the data by age (> 18 years), sex, type of service (inpatient or outpatient care), federated states, and year. Data were collected from 2008 to 2010 and the results reflect the average of the three years. This procedure was carried out to reduce the effect of random variation. Brazilian costs were converted into US dollars using a purchasing power parity basis: PPP 2010: US$1.00 = R$1.7 g .
RESULTS
The influence of alcohol consumption on the occurrence of the selected diseases, measured by PAR, showed a wide variation. The PAR estimates are presented in Tables 2 (male) and 3 ( female). On average, the smallest PAR were for liver cancer and chronic pancreatitis among male adults, and breast cancer and chronic pancreatitis for female adults. Cirrhosis showed the highest PAR for both sexes. Table 4 presents the total costs of the selected diseases, stratified by sex. Of the US$344 million spent on outpatient and inpatient care, 2.4% was attributable to alcohol consumption (≥ 25 g/day of ethanol). The total costs of these diseases were three times higher for women than for men. However, this pattern changed when the fraction attributable to alcohol consumption was considered, with men being responsible for more than 2/3 of the costs.
When these costs were separately analyzed for in-and outpatient care, other patterns were observed. The total costs of hospitalization (Table 4) for the selected diseases were similar between men and women. However, the costs attributable to alcohol consumption were almost six times higher for the male group. For ambulatory services (Table 4) , the total costs related to alcohol consumption were less similar between men and women than that observed for the hospitalization data. However, although women account for more than 80.0% of total costs for the selected diseases, this figure was reduced to 40.0% when the fraction attributable to alcohol consumption was considered.
The cost analysis by disease showed that oropharyngeal cancer, breast cancer, and cirrhosis were responsible for 34.0%, 20.0%, and 15.0% of the costs, respectively ( Table 5 ). The first two diseases were also responsible for the larger proportion of costs in ambulatory services, while the relative impact of breast cancer on hospital costs was small. The most important diseases for hospital costs were cirrhosis and oropharyngeal cancer, followed by hypertension.
The costs attributed to alcohol in all selected diseases represented 0.38% of Brazilian gross domestic product. 
DISCUSSION
The estimates of the PAR showed a wide variation, but when data were analyzed both by capitals or sex, cirrhosis consistently had the largest PAR, followed by oropharyngeal cancer. Liver cancer showed a PAR similar to oropharyngeal cancer among women.
The average annual costs for the eight selected alcohol-related diseases were estimated at US$8 million. Treatment of men contributed significantly more to these costs, mainly because of the hospital sector. Thavorncharoensap et al. 10 also reported a larger contribution of men to health care costs for alcohol related diseases in Thailand. Those authors observed that hospitalizations contributed slightly more than outpatient services, while in our study we observed the inverse. In Sweden, Jarl et al. 4 found that around one-third of the health care costs in 2002 for the treatment of alcohol-related diseases derived from inpatients. The other two-thirds were equally shared by outpatients and primary care.
Comparing the health care costs found in our study with other studies is difficult due to several factors. In the systematic review carried out by Thavorncharoensap et al. 9 (2009), studies were excluded for, among other reasons, not being published in English or if a full description of publication could not be retrieved. Their review found 20 studies that met their criteria, with 12 conducted in developed countries and only one in a developing country (Thailand). Their list of included diseases was larger than ours. For example, several studies included mental and behavioral disorders, injuries, poisoning, and external causes. Moreover, there were important differences in the economic and health care infrastructures, since nearly all these studies were carried out in developed countries. Although in our study cirrhosis had the largest PAR for men and women, it reached the third position for attributable costs. Despite having a much smaller PAR than cirrhosis, oropharyngeal cancer occupied the first position for the costs impacting both hospital and ambulatory sectors. Breast cancer gave the second highest contribution for the costs, mainly because of the ambulatory sector.
Some limitations in our study need to be addressed, most of them resulting from the lack of information for the Brazilian population. First, PAR was estimated using RR estimated by meta-analyses with data from prospective and case-control studies carried out in high income countries. Our assumption is that the effect of alcohol consumption on the risk of the selected diseases is relatively homogeneous among western populations. We estimated PAR based on the RR for a consumption of 25 g/day of ethanol, since the Brazilian survey only provided information on the percentage of adults consuming one or more drinks for women (15 g/day of ethanol) and two or more drinks for men (30 g/day of ethanol). However, the probable impact of this decision is a small underestimation of the risk. Second, we had to assume that confounding factors were controlled when RR were estimated in order to interpret PAR as the proportion of cases that could be prevented if the exposure were eliminated. However, we have no information on how most of the individual studies included in the metaanalyses dealt with this methodological aspect. Third, we did not use exposure by age groups, since precise estimates were unavailable. Finally, the Departamento de Informática do Sistema Único de Saúde (DATASUS -Information Technology Department of the Brazilian Unified Health System) is an administrative database, designed to make and record payments for hospitalizations, rather than for epidemiological purposes. Many limitations regarding this data can be raised such as the quality of the input data, fraud, and duplication of data.
Another limitation concerns the findings of benefits related to moderate consumption of alcohol (e.g., coronary heart diseases) in some studies. Excluding these diseases from the analysis could have overestimated the costs.
The consumption pattern of alcohol in Brazil has been classified as being at a high-risk level 6 . To the best of our knowledge, this is the first study to estimate health care costs of relevant alcohol-related diseases in the SUS. This information is needed not only to improve the estimates of health care costs, but also to quantify the scale of the burden attributable to alcohol consumption on the health system and on society.
